(Nasdaq:HZNP) Horizon Pharma PLC Sets 52 Week High Bar Of $21.10

Horizon Pharma PLC (Nasdaq:HZNP)

August 10th, 2018

Horizon Pharma PLC closed Saturday up 3.93%, a $0.79 increase to close on $20.91. Furthermore it hit a new 52 week high of $21.10. While it is positive news the stock ended higher, the trading volumes were only 0.00% of normal which could be an indication of investor uncertainty. (more…)

(Nasdaq:HZNP) Horizon Pharma PLC Breaks 52 Week High Bar Of $20.25

Horizon Pharma PLC (Nasdaq:HZNP)

August 9th, 2018

Amidst falling markets Horizon Pharma PLC rose $1.96 Wednesday, a 10.79% jump, closing at $20.12. Furthermore it hit a new 52 week high of $20.25. While it is positive news the stock ended higher, the trading volumes were only 0.00% of normal which could be an indication of investor uncertainty. (more…)

Hitting 52 Week High, Horizon Pharma PLC (Nasdaq:HZNP) Close At $17.26

Horizon Pharma PLC (Nasdaq:HZNP)

June 8th, 2018

Amidst rising markets Horizon Pharma PLC went up $0.92 Monday, a 5.63% increase, closing at $17.26. In addition it hit a new 52 week high of $18.11. Horizon Pharma PLC swung 11.10% between high and low. Two technical ‘scores’ for stocks to be wary of are the Altman Z1 and the Piotroski2 scores. HZNP scored quite low for both, which could be…

Horizon Pharma PLC (Nasdaq:HZNP) Breaks 52 Week High Bar Of $16.72

Horizon Pharma PLC (Nasdaq:HZNP)

June 1st, 2018

Amidst rising markets Horizon Pharma PLC closed Saturday up 2.02%, a $0.33 increase to close on $16.63. In addition it hit a new 52 week high of $16.72. Two technical ‘scores’ for stocks to be wary of are the Altman Z1 and the Piotroski2 scores. HZNP scored quite low for both, which could be indicators of trouble down the road (the Altman Z-Score is…

Why Even After 150% Move In PhaseRx Inc. (NASDAQ:PZRX), Shares Are Still Undervalued

PhaseRx Inc. (NASDAQ:PZRX), a small $30M preclinical biotech Market Exclusive initiated coverage on back in September, just climbed 150% in a single day on news of an Orphan drug designation from the Food and Drug Administration (FDA) for its lead candidate targeting a rare genetic liver disease. In 99% of cases, this type of news wouldn’t cause such a spectacular move, especially for a…

Why Horizon Pharma plc Stock Slumped in October

Image source: Getty Images

Why Horizon Pharma plc Stock Slumped in October

Image source: Getty Images

Is Horizon Pharma plc Still a Good Buy?

Image source: Getty Images